First International Bank & Trust Increases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

First International Bank & Trust lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 104.2% during the third quarter, HoldingsChannel.com reports. The fund owned 4,406 shares of the company’s stock after purchasing an additional 2,248 shares during the quarter. Johnson & Johnson makes up 0.3% of First International Bank & Trust’s holdings, making the stock its 27th largest position. First International Bank & Trust’s holdings in Johnson & Johnson were worth $720,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of JNJ. Price T Rowe Associates Inc. MD lifted its holdings in shares of Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after purchasing an additional 3,912,430 shares during the period. FMR LLC lifted its holdings in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after purchasing an additional 3,229,032 shares during the period. GQG Partners LLC lifted its holdings in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after purchasing an additional 2,547,378 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after purchasing an additional 2,093,392 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after purchasing an additional 1,805,632 shares during the period. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.3 %

Johnson & Johnson stock opened at $168.31 on Tuesday. The stock has a market cap of $440.04 billion, a PE ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56. The stock has a 50-day moving average price of $176.07 and a 200 day moving average price of $171.13. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a current ratio of 1.43, a quick ratio of 1.18 and a debt-to-equity ratio of 0.37.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Barclays began coverage on Johnson & Johnson in a report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price for the company. Atlantic Securities reduced their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Raymond James reduced their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Morgan Stanley reduced their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Finally, Citigroup raised their target price on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares in the company, valued at approximately $22,354,891.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares in the company, valued at approximately $6,431,835.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.